PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q1, 2014/15)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
13/EE/0276	A Phase 3B Randomized, OpenLabel MultiCenter Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	4	01/01/2014	Open	Y	Recruitment far exceeded target of 4 (23 patients recruited to date).
11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	30/09/2014	Open	Y	Study already delivered to time and target. There are 29 patients recruited to date.
11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis	2	No Date Agreed With Sponsor	Open	Y	Study delivered to target.
12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment Na?ve Subjects with Chronic He	5	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target.
12/EE/0400	GS-US-334-0109 ? An open label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977	1	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target. 4 patients recruited in total. No date specified in contract; recruitment window linked to unblinding of feeder study.
13/LO/1352	A phase II, open-label, multicenter, randomized study to investigate the efficacy and safety of mpdl3280a (anti-pd-l1 antibody) compared with docetaxel in patients with non-small cell lung cancer after platinum failure	2	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target. 6 patients recruited in total.
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	3	No Date Agreed With Sponsor	Closed - In Follow Up	Y	Study delivered to target. Study has been in follow up since 2008.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (C	5	15/06/2008	Closed - In Follow Up	Y	Study delivered to time and target.
08/H0711/45	A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer	23	24/07/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
08/H1102/75	A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0605/58	Sub Study to study WN25203,using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	31/10/2014	Open	Y	Study delivered to time and target.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered oraly once daily in patients with multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.

10/H1306/5	A phase III open multicentre study to investigate the safety and efficacy of BPL's high purity factor X in the treatement of factor X deficient subjects undergoing surgery.	1	31/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/AL/0322	Phase 2 Active-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer	2	30/10/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0190	A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy	8	15/12/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1502	A Phase 3, Randomized, Double-Blinded, Placebo Controlled 3 arm Study of SAR302503 in Patients with Intermediate-2 or High Risk Primary (PMF), Post Polycythemia Vera (post PV-MF), or Post-Essential Thrombocythemia Myelofibrosis (post ET-MF) with Spl	2	24/08/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1503	A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea.	2	25/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with Telaprevir and Pegasys/Copegus com	5	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/2042	A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy	24	30/09/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA1O1 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainte	2	20/12/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/SC/0161	A randomized, double-blind, placebo controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatment na?ve patients	5	01/11/2011	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/SC/0454	A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Open	Y	Study delivered to time and target.
11/SC/0499	A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythaemia myelofibrosis (PPV MF) or postessential thrombocythaemia myelofibrosis (PET-MF).	1	31/08/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment ?experienced adults with genotype 1 chronic hepat	5	01/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis (	4	31/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Na?ve Subjects with Chroinc Genotype 1 HCV Infection	5	01/04/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/NE/0266	GS-US-334-0133 ? A phase 3 multicenter, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 weeks in treatment naive and treatment experienced subjects with chronic genotype 2 or 3	5	01/09/2012	Closed - Follow Up Complete	Y	Study delivered to time and target.

12/NE/0342	A multicentre, randomised, double blind, placebo-controlled pivotal study to evaluate the efficacy and safety of GFT505 80mg and GFT505 160mg on steatohepatitis in patients with non-alcoholic steatohepatitis (NASH)	6	01/02/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Study delivered to time and target.
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease	10	01/01/2014	Open	Y	Study delivered to time and target.
12/SC/0031	A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4n (v1) - Clinical Protocol AI444042	2	30/04/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/YH/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/05/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	5	31/07/2013	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0552	SinuSys Patency of Maxillary Sinus Ostia Study	6	01/06/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	5	01/05/2014	Open	Y	Study delivered to time and target.
13/LO/0740	A randomized, multicenter, double blind phase 3 study of pd 0332991 (oral cdk 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with er (+), her2 () breast cancer who have not received any prior s	2	30/06/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Tre	4	21/10/2013	Closed - In Follow Up	Y	Study delivered to time and target.
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal AntibodyKW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	3	30/06/2014	Open	Y	Study delivered to time and target.
11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y	Study delivered to time and target. 33 patients recruited in total.
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	26/06/2014	Closed - In Follow Up	Y	Study delivered to time and target. 5 patients recruited in total.
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	02/07/2014	Closed - In Follow Up	Y	Study delivered to time and target. 6 patients recruited in total.
10/H0711/11	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active control Study to Determine the Efficacy and safety of Daclizumab High Yield Process (DAC HYP) versus Avonex? (Interferon ?-1a) in patients wih Relapsing-remitting multiple Sc	6	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target. 7 patients recruited in total.
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Open	Y	Study delivered to time and target. Target reached 12 months ahead of date agreed.
11/LO/1904	A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists	6	31/05/2013	Open	Y	Study still open.
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	1	31/03/2015	Open	Y	Study still open.

12/LO/0098	A randomized, doubleblind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroid	6	01/08/2013	Open	Y	Study still open.
12/WM/0087	Phase I/II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemic Ineligible for Intensive Chemotherapy (RAvVA).	4	01/09/2014	Open	Y	Study still open.
12/YH/0179	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic Ly	2	19/11/2013	Open	Y	Study still open.
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Risistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	1	30/09/2018	Open	Y	Study still open.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	3	31/10/2014	Open	Y	Study still open.
13/NW/0265	A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy (De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemi	7	01/08/2014	Open	Y	Target reached 2 months prior to agreed date.
13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Open	Y	Target reached 4 months prior to agreed date.
12/LO/0980	Protocol EC-FV-06: A randomized double-blind phase 3 trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (pld/doxil?/caelyx?) in combination versus pld in participants with platinum-resistant ovarian cancer	5	31/01/2015	Withdrawn	N/A	Data Safety Monitoring Board recommended early closure of the study and Sponsor agreed.
10/H0405/29	Fistula-In-Ano Trial to compare Surgisis anal fistula plug versus surgeon's preference for transsphincteric fistula-in-ano	4	31/10/2014	Open	N/A	Date agreed to recruit to target not yet passed.
11/AL/0120	An open-label, multicenter, randomized, phase 3 study of S-1 and cisplatin compared with 5-FU and cisplatin in patients with metastatic diffuse gastric cancer previously untreated with chemotherapy	3	06/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	10	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
11/H0606/1	Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma ? a randomised phase III trial	1	30/11/2014	Open	N/A	Date agreed to recruit to target not yet passed.
11/LO/0551	A phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid tumors	10	31/01/2015	Open	N/A	Date agreed to recruit to target not yet passed.
11/LO/1776	Urinary Proteomics for HIGH Risk pregancies (UP HIGH R) - PEACHES	60	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
11/NE/0214	Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms	6	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.
11/SS/0092	Trial of BIBW 2992 in suspected mutant EGFR lung cancer patients unfit for chemotherapy	4	15/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/0984	A Randomized, Open-Label Phase 2 Study Of The Ido Inhibitor Incb024360 Versus Tamoxifen For Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma Or Fallopian Tube Cancer Following Complete Remission With F	5	31/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1078	A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma patients.	5	31/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.

12/LO/1158	Bevacizumab And Combination Chemotherapy in rectal cancer Until Surgery: A Phase II, Multicentre, Openlabel, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined HighRisk Cancer of the Rectum	3	01/10/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1173	An Open Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer	10	31/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE) Short	10	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (iSpot)	8	24/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologi	3	01/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut	5	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/NW/0555	Randomized Phase II Study of BEZ235 vs. everolimus in Advanced Pancreatic Neuroendocrine Tumors	2	15/04/2015	Open	N/A	Date agreed to recruit to target not yet passed.
12/SS/0109	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches	118	15/10/2019	Open	N/A	Date agreed to recruit to target not yet passed.
12/SW/0378	Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	6	31/10/2014	Open	N/A	Date agreed to recruit to target not yet passed.
12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident	100	01/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/EN/0348	Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surfa	10	28/11/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0365	An efficacy and mechanism evaluation study for Levosimendan for the prevention of accute organ dysfunction in sepsis (LeoPARDS)	24	31/08/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1011	Molecular imaging coupled with advanced image processing for response assessment to transcatheter arterial chemoembolisation in patients with HCC	10	01/07/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1091	Non-invasive Pressure-Volume Analysis (NIPVA): extending comprehensive left ventricular pump function assessment to more patients and settings	60	31/08/2014	Suspended	N/A	Date agreed to recruit to target not yet passed.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Tre	6	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1305	Systematic Assessment of Pulmonary Artery Haedodynamics using Wave Intensity Analysis	36	12/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1340	Defining a gold standard for ischaemia: Effects of interventional revascularisation versus optimum medical therapy on exercise capacity in patients with stable coronary artery disease.	150	01/10/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1351	Patient-specific virtual reality rehearsal prior to EVAR: Influence on technical and non-technical operative performance.	30	01/08/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1375	A randomised controlled trial to evaluate the impact of psychological support intervention after chemotherapy for women with ovarian cancer	19	30/11/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1639	Patient matched osteotomy to correct angular deformities in knee arthrosis	7	30/11/2014	Suspended	N/A	Date agreed to recruit to target not yet passed.

13/LO/1725	Prospective, multi-center, double blind, ranodmised study to test the safety of deferral of stenting in a physioogical non-significant lesions in a clinical population of intermediate senoses using iFR and FFR	150	31/01/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/lo/1816	Intraocular Pressure And Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost)in patients with Ocular hypertension or Glaucoma: A Randomised, single masked,	10	01/05/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW0697	PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	8	14/02/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0111	FOCUS4 ? Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme	155	30/11/2017	Open	N/A	Date agreed to recruit to target not yet passed.
13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera? plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or M	3	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/SW/0199	A randomised clinical trial to compare early verus delayed endovenous treatment of superficial venous reflux in patients with chronic venous ulceration	40	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/WA/0178	A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable	5	31/12/2014	Open	N/A	Date agreed to recruit to target not yet passed.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	2	31/07/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/WM/0017	Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism	29	30/09/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/YH/0275	Revitive for the treatment of venous insufficiency	20	01/07/2014	Open	N/A	Date agreed to recruit to target not yet passed.
14/SC/0037	A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficiacy and safety study of gantenerumab in subjects with mild Alzheimer's disease	6	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/SC/0038	PET imaging substudy associated with: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficiacy, and safety study of gantenerumab in patients with mild Alzheimer's disease	5	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/YH/0034	IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI32765) in Bcell Receptor Pathway Inhibition in CLL.	2	01/04/2015	Open	N/A	Date agreed to recruit to target not yet passed.
10/H0703/32	Does 3D imaging of the cervix give more accurate cervical measurements in the assessment of risk of preterm labour in a high risk population?	350	01/11/2014	Closed - Follow Up Complete	N/A	Date agreed to recruit to target not yet passed.
12/WS/0180	A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibit	2	12/03/2015	Closed - Follow Up Complete	N/A	Date agreed to recruit to target not yet passed.
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	1	31/12/2018	Open	N/A	Date agreed to recruit to target not yet passed. Rare diease patient group. We screen regularly but no eligible patients identified.
12/SC/570	CFTY720D2406: Long-term, prospective, non-interventional, multinational, parallel-cohort study monitoring safety in patients with MS recently initiated with fingolimod once daily or treated with another approved disease-modifying therapy	50	01/06/2015	Open	N/A	Date agreed to recruit to target not yet passed. There are 44 recruits to date.
12/SC/0569	CFTY720D2405 TRANSITION: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod	15	14/09/2015	Open	N/A	Date agreed to recruit to time and target not yet passed.
13/NE/0125	PRESTO Neo.1.C/E	8	01/08/2014	Open	N/A	Date agreed to recruit to time and target not yet passed.

13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	5	30/09/2014	Open	N/A	Date agreed to recruit to time and target not yet passed.
13/SC/0589	TURBO - Optimisation of Onpulse technology for patients with post surgical or vascular oedema	10	30/07/2014	Open	N/A	Date agreed to recruit to time and target not yet passed.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subc	5	31/08/2016	Open	N/A	Date agreed to recruit to time and target not yet passed.
14/SC/0132	A phase I, open label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy termination.	6	31/10/2014	Open	N/A	Date agreed to recruit to time and target not yet passed.
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	2	31/08/2016	Open	N/A	Date agreed to recruit to time and target not yet passed.
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	12	31/05/2015	Open	N/A	Date agreed to recruit to time and target not yet passed.
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	6	No Date Agreed With Sponsor	Open	N/A	No date agreed with sponsor.
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	5	No Date Agreed With Sponsor	In set up	N/A	No date agreed with sponsor.
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	30	No Date Agreed With Sponsor	Open	N/A	No date agreed with sponsor.
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.	6	No Date Agreed With Sponsor	Open	N/A	No date agreed with sponsor. Extended negotiation over contract/budgets.
13/LO/0223	A combined retrospective and prospective post marketing surveillance study in patients using Temperature controlled Laminar Airflow (TLA) - Protexo Registry	400	No Date Agreed With Sponsor	Open	N/A	No date agreed with sponsor. There are 5 recruited to date.
09/H0711/8	CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care	200	No Date Agreed With Sponsor	Open	N/A	No date agreed with sponsor. There are 7 recruited to date.
13/SW/0124	A performance evaluation study of UROSENS MCM5-ELISA for the detection of prostate cancer in patients with known disease and in those presenting with raised serum prostate-specific antigen and/or abnormal prostate gland morphology	19	28/02/2014	Open	N/A	No date agreed. There 13 recruited to date.
11/LO/1456	A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virlogic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatiatis C Infection (Gilead HCV Registry 0123 Non- Responders)	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor as recruitment window is linked to feeder studies.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor.
12/EE/0231	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N?Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Withdrawn	N/A	No target or date agreed with sponsor.
12/LO/1889	Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progre	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor.
13/EE/0365	Investigation of newly developed 1- and 2-piece convex ostomy products in subjects with ileostomy	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Withdrawn	N/A	No target or date agreed with sponsor.
13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer?s Disease (Prodromal AD).	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor.

13/nw/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate G	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor.
13//YH/0174	A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Withdrawn	N/A	No target or date agreed with sponsor. Site was unable to secure resources to conduct the study, and withdrew from trial.
12/EE/0274	Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor. There are 4 patietns recruited.
13/EM/0374	A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Open	N/A	No target or date agreed with sponsor. There have been 12 patients recruited to date. Although team was consenting and screening early on, there was a high drop-out rate.
1/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	No Target Agreed With Sponsor	No Date Agreed With Sponsor	Closed - In Follow Up	N/A	No target or date agreed with sponsor. There were 12 patients recruited.
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	2	30/09/2014	Withdrawn	N/A	Sponsor closed study for safety reasons - phase II will not be happening in UK due to safety data from phase I. Study closed/withdrawn by sponsor.
12/LO/0923	A Phase 3, randomized, doubleblind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castrationresistant prostate cancer	3	30/06/2015	Withdrawn	N/A	Sponsor paused screening 2 weeks after R&D approval at site, and subsequently closed recruitment preamturely at all sites.
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (mtx) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (ra) who have demonstrated an ina	5	01/01/2014	Open	N	2 patients recruited to date.
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Closed - In Follow Up	N	2 patients recruited to date.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	17	30/06/2014	Open	N	4 patients recruited to date.
13/SC/0291	An open label, phase I study to evaluate the impact of severe hepatic impairment on the pharmacokinetics and safety of vemurafenib in BRAFV600 mutation positive cancer patients	10	30/04/2017	Withdrawn	N	Abandoned before opening to recruitment.
13/LO/1290	A Followup Study to Assess Resistance and Durability of Response to AbbVie DirectActing Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	1	01/08/2014	Withdrawn	N	Closed by Sponsor due to recent results of a related study indicating that there would be need for fewer subjects to answer the study question.
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena)	5	01/02/2014	Closed - Follow Up Complete	N	Eligible patients were identified but none agreed/consented to participate or passed screening criteria.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosis (Protocol No: CBAF312A230	6	30/04/2014	Open	N	IMP supply delays. 5 patients recruited to date; target of 6 is to be reached in September 2014.

13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	4	31/03/2014	Closed - Follow Up Complete	N	Initially restrictive inclusion/exclusion criteria in original protocol. Substantial Amendments submitted in order to broaden potential patient population. Difficult population group - very sick inpatients, normally on ITU.
12/NW/0802	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day	5	01/02/2015	Withdrawn	N	Problem with external contractor supplying MRI services and delays in negotiating contract. Study now abandoned.
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	4	No Date Agreed With Sponsor	Closed - Follow Up Complete	N	Proposed study regimen would be under-treating patients in relation to another study with the same IMP; therefore difficult to justify enrolling patients into this study. Sponsor is aware of this issue.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	1	31/08/2014	Open	N	Rare disease study.
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	6	01/10/2014	Open	N	Rare disease study.
12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor Villa Variant (813), in adult Hemophilla A and B Subjects with or without inhibitors	1	30/04/2014	Open	N	Rare disease study. Study suspended by Sponsor before first patient consented at all sites. Strict/difficult dosing schedule. Major protocol amendments approved May 2013.
13/LO/0830	Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment na?ve genotypes 1, 2, 3 or 4 in subjects co-infected	2	30/04/2014	Open	N	Site entered trial late so this has limited the genotype groups that are available to be recruited.
13/LO/0501	A phase 2, randomized, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of maribavir versus valganciclovir for treatment of CMV infections in transplant recipients who do not have CMV organ disease	1	31/03/2014	Closed - Follow Up Complete	N	Sponsor required extensive protocol-specific training in various electronic systems; delayed set-up. Recruitment closed by Sponsor before site was able to enrol a patient.
13/LO/0097	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with advanced liver fibrosis but not cirrhosi	5	No Date Agreed With Sponsor	Closed - Follow Up Complete	N	Study burden on patients excessive / heavy. Difficult for patients to consent and study since closed by Sponsor.
13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like moleculae 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	5	01/12/2013	Closed - Follow Up Complete	N	Study burden on patients excessive / heavy. Difficult for patients to consent and study since closed by Sponsor.
13/SC/0249	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects with compensated cirrhosis secondary to non a	5	No Date Agreed With Sponsor	Closed - Follow Up Complete	N	Study burden on patients excessive / heavy. Difficult for patients to consent and study since closed by Sponsor.
12/LO/0720	A Phase 1 Randomised Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis	4	30/06/2014	Suspended	N	Study design modified by Sponsor after site opened / site suspended recruitment pending clarifications.
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N	Target reached but 2 months later than agreed date.

10/H0711/6	Cardiovasular outcomes to evaluate the potential of aleglitazar to reduce cardiovasular risk in patients with a recent acute coronary syndrome (ACS) event & type 2 diabetes (T2D)	60	30/05/2011	Closed - Follow Up Complete	N	
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	6	01/01/2013	Open	N	
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infect	10	19/12/2013	Closed - In Follow Up	N	
12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	30/06/2014	Open	N	
12/NW/0682	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia	8	01/07/2013	Closed - Follow Up Complete	N	
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	4	01/01/2014	Open	N	
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	1	28/02/2014	Closed - In Follow Up	N	
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6	31/05/2014	Open	N	
13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chroinic Hepatitis C Genotype 1b who are Treatment Na?ve or Prior Re	4	01/11/2013	Closed - In Follow Up	N	
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Open	N	
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Longterm Safety and Efficacy of AMG 145	8	01/01/2014	Open	N	
13/WA/0064	A performance evaluation study of UROSENS MCM5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	15/01/2014	Open	N	